Medicine and Dentistry
Mycosis
100%
Chronic Pulmonary Aspergillosis
67%
Aspergillus
56%
Invasive Aspergillosis
48%
Human Immunodeficiency Virus
43%
Diseases
40%
Prevalence
38%
Infection
37%
Allergic Bronchopulmonary Aspergillosis
35%
Diagnosis
33%
Aspergillosis
24%
Cryptococcal Meningitis
22%
Systemic Mycosis
21%
Asthma
20%
Histoplasmosis
20%
Antifungal Agent
20%
Sensitization
19%
Lung Aspergillosis
19%
Itraconazole
19%
Severe Asthma
17%
Amphotericin B
17%
Lung Tuberculosis
15%
Antifungal Therapy
13%
Candidemia
13%
Pneumocystis Pneumonia
13%
Vagina Candidiasis
12%
Immunocompromised Patient
11%
Chronic Obstructive Pulmonary Disease
11%
Cryptococcosis
10%
Voriconazole
10%
High-Risk Population
10%
Cohort Effect
10%
Human Immunodeficiency Virus Infection
9%
Medical Mycology
9%
Candidiasis
8%
Tinea Capitis
8%
Esophageal Candidiasis
8%
Pyrrole
8%
Polymerase Chain Reaction
8%
Mucormycosis
7%
Pneumocystis Jirovecii
7%
Pathogen
7%
Sputum
7%
COVID-19
7%
Aspergillus fumigatus
7%
Fungal Keratitis
7%
Aspergilloma
6%
Lateral Flow Assay
6%
Opportunistic Infection
6%
Cystic Fibrosis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Mycosis
79%
Aspergillus
59%
Lung Aspergillosis
56%
Disease
56%
Invasive Aspergillosis
44%
Itraconazole
43%
Amphotericin B
38%
Prevalence
38%
HIV
38%
Asthma
34%
Infection
31%
Aspergillus fumigatus
29%
Antifungal Agent
28%
Allergic Bronchopulmonary Aspergillosis
27%
Fluconazole
22%
Aspergillosis
20%
Pyrrole
18%
Voriconazole
17%
Candida
16%
Cryptococcal Meningitis
14%
Histoplasmosis
13%
Chronic Obstructive Lung Disease
12%
Vagina Candidiasis
12%
Candidemia
12%
Lung Tuberculosis
10%
Triazole
10%
Flucytosine
9%
Aflatoxin
9%
Pneumocystis Pneumonia
8%
Posaconazole
8%
Thrush
8%
Tinea Capitis
8%
Systemic Mycosis
7%
Antifungal Therapy
7%
Human Immunodeficiency Virus Infection
7%
Keratomycosis
7%
Candida Albicans
7%
Candidiasis
7%
Micafungin
7%
2 (2,4 Difluorophenyl) 1 [3 [2 [4 (2,2,3,3 Tetrafluoropropoxy)phenyl]vinyl] 1,2,4 Triazol 1 Yl] 3 (1,2,4 Triazol 1 Yl) 2 Propanol
6%
Esophagus Candidiasis
6%
Invasive Candidiasis
6%
Immunoglobulin G Antibody
6%
Mucormycosis
6%
Immunocompromised Patient
6%
Infectious Agent
6%
Adverse Event
6%
Opportunistic Infection
6%
Enzyme-Linked Immunosorbent Assay
5%
Malignant Neoplasm
5%
Immunology and Microbiology
Aspergillus
90%
Aspergillus fumigatus
51%
Allergic Bronchopulmonary Aspergillosis
40%
Prevalence
40%
Human Immunodeficiency Virus
40%
Asthma
32%
Sensitization
29%
Severe Asthma
27%
Candida
18%
Minimum Inhibitory Concentration
17%
Infectious Agent
16%
Pneumocystis
13%
Sputum
12%
Human Immunodeficiency Virus Infection
9%
Meningitis
9%
Pneumocystis Jiroveci
8%
Mouse
8%
Histoplasma
8%
Antifungal Susceptibility
7%
Monospecific Antibody
7%
Antifungal Resistance
7%
Immunoglobulin E
7%
Medical Mycology
6%
Ajellomyces capsulatus
6%
Opportunistic Infection
6%
Candida Albicans
6%
Mould
6%
Polymerase Chain Reaction
6%
CD4 Lymphocyte Count
6%
Lateral Flow Assay
6%
Immunoglobulin G Antibody
6%
Enzyme-Linked Immunosorbent Assay
6%
Allergen
5%
Real Time Polymerase Chain Reaction
5%
Disease Burden
5%
Medline
5%
Awareness
5%
Filamentous Fungus
5%
HIV/AIDS
5%
Enzyme Immunoassay
5%
Keratitis
5%
Inoculum
5%
Candida Glabrata
5%